Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Ondra Health vs Nova MD

Two GLP-1 deals, scored on the same six factors. Ondra Health lands a Value Score of 92, Nova MD a 73. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Ondra Health

#2 · Grade A+ · Best Value

Est. first month

$93/mo

Save ~93% vs brand-name
Get this deal Full Ondra Health review →
VS

Nova MD

#178 · Grade C+ · Watch List

Est. first month

From $125/mo (3-month plan, compounded)

Save ~91% vs brand-name
Get this deal Full Nova MD review →

The verdict

Better value: Ondra Health

Ondra Health takes it on Value Score, 92 to 73 an est. $93/mo first month, with no teaser step-up baked in. Nova MD isn't out of it: Shoppers who want lowest 3-month compounded pricing with an explicit microdose program.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealOndra HealthNova MD
Value Score92 (A+)73 (C+)
Est. first month$93/moFrom $125/mo (3-month plan, compounded)
Save vs brand-name~93%~91%
Semaglutide$93/moFrom $125/mo (3-month plan, compounded)
Tirzepatide$166/moFrom $199/mo (3-month plan, compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

96
Lowest Real Price
87
Ondra Health: 96. Nova MD: 87.
88
No Teaser-Rate Bait
62
Ondra Health: 88. Nova MD: 62.
98
Nationwide Availability
45
Ondra Health: 98. Nova MD: 45.
92
Both Molecules
92
Ondra Health: 92. Nova MD: 92.
84
Easy Cancellation
58
Ondra Health: 84. Nova MD: 58.
84
Reputation
68
Ondra Health: 84. Nova MD: 68.

Ondra Health

The cheapest flat semaglutide sticker we track ($93) — LegitScript-certified, all 50 states, and it still offers brand-name access.

Why it's a deal

  • Lowest disclosed flat semaglutide price in the roster ($93/mo) — no teaser step-up
  • LegitScript-certified and available in all 50 states
  • Offers FDA-approved brand-name access alongside compounded
  • Tirzepatide is competitive too at $166/mo

The fine print

  • Newer name with a shorter public track record than the established flat-fee brands
  • No oral/sublingual route for the needle-averse

Nova MD

Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.

Why it's a deal

  • On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
  • $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
  • $50 off first tirzepatide order shown publicly
  • Explicit microdose / low-dose program for both semaglutide and tirzepatide
  • Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1

The fine print

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy not named — only 'accredited facilities'
  • LegitScript certification not confirmed (only 'Licensed US Providers' claims)
  • Per-state availability not listed
  • Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic
Get the Ondra Health deal Get the Nova MD deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Ondra Health is ranked on the Ondra Health alternatives board, and the same list for the other side is on alternatives to Nova MD.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.